Abstract:BackgroundHybrid therapy has recently attracted widespread attention. However, many issues require further exploration. For example, research in regions with high antibiotic resistance rates is limited, and the correlation between eradication efficacy and antibiotic resistance remains unclear. The aim of this study was to determine the efficacy, compliance, safety, and risk factors of hybrid therapy as first-line regimen in a region with high antibiotic resistance rates. Materials and MethodsThis prospective study was conducted in a tertiary hospital between January 2014 and June 2015. A total of 196 patients with dyspepsia but without prior eradication therapy received hybrid regimen (esomeprazole 20 mg and amoxicillin 1000 mg twice daily for 14 days with the addition of clarithromycin 500 mg and tinidazole 500 mg twice daily for the final 7 days). All patients underwent Helicobacter pylori culture, antibiotic susceptibility testing and cytochrome P450 isoenzyme 2C19 polymorphism testing. ResultsHybrid therapy achieved eradication rates of 77.0% (95% confidence interval (CI), 70.9-83.7%) in intention-to-treat (ITT), 83.9% (78.9-88.9%) in modified ITT and 86.0% (80.2-91.3%) in per-protocol analyses in a setting with high antibiotic resistance rates (amoxicillin 2.0%, clarithromycin 44.9%, metronidazole 67.3% and dual clarithromycin and metronidazole 33.3%). Adverse reactions occurred in 31.9% patients and 2.7% discontinued medications due to adverse reactions. Good compliance was achieved by 92.0%. Multivariate analyses identified clarithromycin resistance (odds ratio, 3.494; 95% CI, 1.237-9.869), metronidazole resistance (3.012; 1.013-12.054) and poor compliance (5.840; 1.126-30.296) as independent predictors of treatment failure. The eradication rate with dual clarithromycin and metronidazole resistance (70.2%) was markedly decreased compared to isolated clarithromycin resistance (87.5%), isolated metronidazole resistance (88.6%), or dual susceptibility (96.4%) (p = .014). ConclusionsDespite good compliance and safety, hybrid therapy as first-line regimen in populations with high antibiotic resistance rates had unsatisfactory efficacy, primarily due to dual clarithromycin and metronidazole resistance.

Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

The Ideal Helicobacter pylori Treatment for the Present and the Future

Review article: the global emergence of Helicobacter pylori antibiotic resistance

Current and Future Treatment of Helicobacter pylori Infections

The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta‐analysis

Strategy for the Treatment of Helicobacter pylori Infection

Is Tailored Therapy Based on Antibiotic Susceptibility Effective ? a Multicenter, Open-Label, Randomized Trial

Treatment of Helicobacter pylori infection: Past, present and future

Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China.

Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for Helicobacter pylori Infections

Recent progress in Helicobacter pylori treatment

Helicobacter pylori treatment in the era of increasing antibiotic resistance

Eradication of Helicobacter pylori: recent advances in treatment

Revolution of Helicobacter pylori treatment

Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances

From Antibiotic Resistance to Antibiotic Renaissance: A New Era in Helicobacter pylori Treatment

Treatment of Helicobacter pylori infection: A clinical practice update

Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates.

Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents

Treatment of Helicobacter pylori infection: a clinical practice update.